Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.
Details
News Market Reaction – SGMT
On Jan 8, the day this news came out, SGMT closed 0.91% above the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Conference dates
- January 8–10, 2026
- 10th Annual MASH-TAG Conference schedule
- Poster date
- January 10, 2026
- Scheduled presentation date for denifanstat poster
- Fibrosis stage
- F3 MASH
- Patient subgroup with ≥2-stage fibrosis improvement
- Fibrosis stage
- qFibrosis stage 4 MASH
- Advanced fibrosis patients with improved liver fibrosis and biomarkers
- Trial phase
- Phase 2b
- FASCINATE-2 clinical trial of denifanstat in MASH
- Fibrosis improvement
- ≥2-stage improvement
- Reported fibrosis benefit in F3 MASH patients on denifanstat
- Poster number
- MASHTAG.2026.A23
- Identifier for denifanstat poster at MASH-TAG 2026
- 52-week range
- $1.73–$11.41
- SGMT 52-week low and high before this news
Historical Context
-
Positive Phase 1 PK results for denifanstat and resmetirom combination.
-
Exclusive global license for innovative resmetirom API forms.
-
China NMPA acceptance of NDA for denifanstat in moderate to severe acne.
-
Phase III acne trial met all primary and key secondary endpoints.
-
Inducement stock option grants to new employees under Nasdaq rules.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
qfibrosis medical
phase 2b medical
fatty acid synthase (fasn) inhibitor medical
biomarkers medical
poster presentation technical
clinical trial medical
metabolic and fibrotic pathways medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat.
MASH-TAG 2026 Poster Presentation Details:
| Title: | Denifanstat elicited a significant ≥2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial |
| Presenting Author: | Rohit Loomba, M.D., M.H.Sc., University of California San Diego |
| Poster number: | MASHTAG.2026.A23 |
| Date: | Saturday, January 10, 2026 |
| Location: | The Chateaux Deer Valley, Park City, Utah |
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom was tested in a Phase 1 PK clinical trial and is planned to be developed for patients with MASH cirrhosis (F4). TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
MASH is a progressive and severe liver disease which is estimated to impact more than 265 million people worldwide. MASH is characterized by the build-up of fat in the liver and various degrees of inflammation and fibrosis along with systemic metabolic changes including dyslipidemia (increased fat levels in blood) and insulin resistance. Patients with moderate to severe disease who have advanced fibrosis (F3) or cirrhosis (F4) have the highest risk of liver-related outcomes such as decompensation, hepatocellular carcinoma, and liver transplantation. There are few approved treatments for non-cirrhotic MASH (stages F1, F2 and F3 fibrosis) and no approved treatments for MASH cirrhosis (F4).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Sagimet Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Sagimet Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.